在复发性多发性硬化症的治疗中不断发展的概念
Giancarlo Comi1, Marta Radaelli1, Per Soelberg Sørensen2
1Department of Neurology and Institute of Experimental Neurology, San Raffaele Hospital, Milan, Italy.
Lancet (London, England)
|November 28, 2016
概括
多发性硬化症 (MS) 的治疗已经发展到不需要临床或MRI活动,需要早期干预. 个性化治疗策略至关重要, 考虑疾病因素和患者个人资料, 以最大限度地提高效益并最大限度地降低风险.
科学领域:
- 神经学
- 免疫学
- 药理学
背景情况:
- 在过去的20年里, 多发性硬化症 (MS) 的治疗有了显著的进步.
- 治疗目标已经从减少复发转向实现完全的疾病缓解 (没有临床或MRI活动).
研究的目的:
- 突出现代多发性硬化症治疗选择的复杂性.
- 强调了解药物机制和风险/益处概况的重要性.
- 引导神经科医生优化个体患者的治疗策略.
主要方法:
- 对多发性硬化症的当前治疗方法的审查.
- 对不断变化的治疗环境和目标进行分析.
- 考虑影响治疗选择的因素,包括疾病活动,病史和风险耐受性.
主要成果:
- 现已广泛使用有效的疾病修饰疗法.
- 在MS的炎症阶段,早期开始治疗至关重要.
- 个性化治疗选择需要仔细评估疾病预后因素,并发症以及患者特异性考虑.
结论:
- 优化多发性硬化症治疗需要全面了解疾病机制和个体病人的因素.
- 密切的临床监测对于早期识别亚优反应至关重要.
- 治疗策略应适应,以确保患有多发性硬化症的患者获得最大的益处和最小的风险.
相关概念视频
Myasthenia Gravis: Overview and Treatment
3.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.2K
Drug Therapy
361
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
361
Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Classification of Illness
9.2K
The meaning of illness is individualized to each person who experiences an alteration in health. In contrast, disease is a medical term indicating a pathological change in the structure and function of the body or mind. It is a condition that has specific symptoms and boundaries.
An illness is a response to a disease in which the person's level of functioning is changed compared with a previous level. The general classification of illness includes acute and chronic.
Acute illness is severe...
An illness is a response to a disease in which the person's level of functioning is changed compared with a previous level. The general classification of illness includes acute and chronic.
Acute illness is severe...
9.2K
Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Long-term Potentiation
3.8K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
Hebbian LTP
LTP can occur when...
Hebbian LTP
LTP can occur when...
3.8K


